Biased Ligands. Better Drugs.

TRV130 - Mu Opioid Biased Ligand for Acute Pain

ProductTargetIndicationLead OpPreclinPhase 1Phase 2Phase 3
TRV027Angiotensin II
type 1 receptor
Acute Heart Failureintravenous
TRV130Mu-opioid
receptor
Postoperative Painintravenous
TRV734Mu-opioid
receptor
Moderate to Severe Painoral
Delta OpioidDelta-opioid
receptor
Parkinson's, Migraine, Neuropathic Pain 
Collaboration with Actavis

TRV130 is an intravenous G protein biased ligand that targets the mu opioid receptor. Trevena is developing TRV130 for the treatment of moderate to severe acute pain where intravenous therapy is preferred, with a clinical development focus in acute postoperative pain.

View TRV130 Publications

Recent TRV130 News

Related Events

Copyright © Trevena, Inc.